Medtronic Plc., LivaNova PLC, CryoLife, Inc., and Edwards Lifesciences Corporation, among others, are the major players in the global aortic valve replacement market.
The global aortic valve replacement market is expected to grow at a CAGR of 12.06% in the forecast period of 2024-2032. As per the analysis of Expert Market Research, the market is expected to be driven by the growing prevalence of cardiovascular diseases.
The growing prevalence of cardiovascular issues owing to the increasing stress levels and poor eating habits, among others, is driving the market for aortic valve replacement. Advancements in medical technology are driving the demand for minimally invasive and simple processes like Transcatheter Aortic Valve Replacement (TAVR), which reduces recovery time while offering a high success rate. Moreover, the rising use of TAVR to decrease the symptoms of aortic valve stenosis and restore blood flow is expected to propel the market growth. The surging commercialisation of the technology in both developed and developing countries is likely to significantly contribute to the market growth of aortic valve replacement in the forecast period.
In September 2020, Medtronic announced the launch of the Evolut™ FX TAVR system, its self-expanding and new generation TAVR system, in the United States. The new system offers enhanced ease of use as well as predictable valve deployment for physicians. It also updates various features of the Evolut platform, including a redesigned catheter tip, a delivery system with enhanced flexibility, and the lowest delivery profile. Through this, the company advances TAVR delivery systems, optimises patients’ outcomes, and improve the reliability of aortic valve replacement procedure.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Medtronic plc is a global healthcare technology company. With over 90,000 employees in 150 countries, the company has served more than 72 million patients. It has invested about USD 2.5 billion in R&D investments, more than 300 clinical trials, and over 49,000 patents in its portfolio. The company aims to utilise biomedical engineering for the development and manufacturing of instruments that can improve the quality of life of patients.
|London, United Kingdom
LivaNova is a medical technology company that develops devices used for cardiac surgery and neuromodulation. With a wide presence in over 100 countries, the company employs 3000 people to improve the quality of life of patients. Some of the leading therapeutic areas of the company include heart failure, advanced circulatory support, obstructive sleep apnoea, and cardiopulmonary, among others.
|Georgia, United States
CryoLife is a leading medical device company that provides mechanical heart valves for aortic replacement, cardiac lasers for refractory angina treatment, and surgical sealants and adhesives. It employs 700 employees from 11 countries and has representations in 85 countries across the globe. The business verticals of CryoLife include aortic valve replacements, cardiac and vascular allografts, autologous pericardium, paediatric conduits, CardioGenesis and more.
|California, United States
Edwards Lifesciences is the global leader in patient-focused medical innovations for cardiovascular and critical health issues. The company actively partners with healthcare providers to design innovative and advanced medical products. With a wide presence in about 100 countries in the world, the company provides its solutions to clinicians.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.